Santos's Barossa Gas Pipeline Delayed by Australian Court
By Stuart Condie
SYDNEY--Santos's attempt to lay a pipeline through a gas field off Australia's north coast has been held up after a court granted an interim injunction delaying the start of the project.
The Australian energy explorer on Thursday said that Australia's Federal Court had granted an injunction delaying the commencement of the laying of the Barossa gas export pipeline until Nov. 13, following allegations that the project could affect submerged sites of cultural importance to the indigenous inhabitants of the nearby Tiwi Islands.
Tiwi Islander Simon Munkara wants the court to force Santos to revise and resubmit its environmental plan for the project, the company said.
The court will decide on Nov. 13 whether to further extend the injunction. Santos said a pipe-laying vessel will remain in Darwin, in Australia's Northern Territory, pending the decision.
The company said it will assess any impact to the project's cost guidance and schedule if the injunction is extended.
Write to Stuart Condie at stuart.condie@wsj.com
(END) Dow Jones Newswires
November 02, 2023 00:06 ET (04:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks